Rheumatoid Arthritis DMARD Intervention and UtilizationStudy

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis. The primary purpose of this study is to estimate the incidence of serious adverse experiences and adverse experiences of interest in patients with rheumatoid arthritis (RA) treated with ENBREL®.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Collaborators: Immunex Corporation; Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Antirheumatic Agents; Etanercept

Criteria

Inclusion Criteria:

• Fulfillment of the 1987 American Rheumatism Association criteria for RA

• Currently requiring the addition of ENBREL® therapy (to be taken alone or in addition to their current DMARD therapy)

Exclusion Criteria:

• Currently or previously enrolled in RADIUS 1

• Currently enrolled in a clinical trial where treatments or patient visits are imposed by a protocol

• Active infections

• Known allergy to ENBREL® or any of its components

• Current treatment with ENBREL®

• Patients who have previously been demonstrated to be intolerant of or refractory to ENBREL® therapy

• Nursing or pregnant women